Abstract 153P
Background
Within BRCA carriers, there are data suggesting that not all alterations confer the same risk of breast or ovarian cancer. In addition, the localization of the mutation as a biomarker of response to targeted therapies such as iPARP is in the process of being validated. The distribution of mutations according to the functional domain in which they are located may be a good method for establish their role in cancer risk.
Methods
We included all carriers from the registry of the Hereditary Cancer Unit. Functional domains (dom) of BRCA1 were defined as: Really Interesting New Gene (RING) from aa 8-96; DNA-binding dom (DBD) from aa 452-1092; and BRCA1 C terminal (BRCT) from aa 1650-1863 Functional doms of BRCA2 were defined as: PALB2-BD dom from aa 21-39, RAD51-binding dom (RAD51-BD) from aa 900-2000, and DBD from aa 2459-3190.
Results
284 carriers were located. 66% women, 55% BRCA1 mutation carriers (mc). Of these, 63% healthy carriers (hc), half of whom were women. Among the BRCA1 muts, 55% of breast cancer (bc) were associated with BRCT muts compared with 5.5% in DBD. In the BRCT dom, the mean age at diagnosis (dx) of bc was 44 years, with 35% of luminal tumors. Among hc, only 33% were older than the mean age at dx. Among the BRCA2 muts, 61% of the cases with bc were associated with the RAD51-BD dom compared to 10% in the DBD dom. In the RAD51-BD dom, the mean age at dx of bc was 51 years, with 11% of cases being Her-2 positive and 29% triple negative. Among hc, only 40% were older than the median age at dx. As for ovarian cancer, a more heterogeneous pattern was observed, although again, the doms with the most cases were BRCT and RAD51-BD. Table: 153P
BRCA 1 | BRCA 2 | TOTAL | |||||||||
RING | DBD | BRCT | Others | Total | PALB2-BD | RAD51 | DBD | Others | Total | ||
Healthy carrier | 3 | 21 | 41 | 38 | 103 | 2 | 55 | 5 | 19 | 81 | 184 |
Breast | 1 | 2 | 20 | 13 | 36 | 1 | 17 | 3 | 7 | 28 | 64 |
Ovarian | 1 | 2 | 7 | 8 | 18 | 0 | 6 | 2 | 4 | 12 | 30 |
Pancreas | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 2 | 3 | 4 |
Other tumors* | 0 | 1 | 0 | 0 | 1 | 0 | 6 | 0 | 1 | 7 | 8 |
Total | 5 (3.1%) | 26 (16.4%) | 69 (43.4%) | 59 (37.1%) | 159 | 3 (2.3%) | 85 (64.9%) | 10 (7.6%) | 33 (25.2%) | 131 | 290 |
Mean age at diagnosis | 53 | 63 | 44 | 43.9 | 46 | 51 | 51 | 43 | 49 | 49 | 47 |
*Other tumors: cholangiocarcinoma, medulloblastoma, urotelial, astrocitoma, cervical and melanoma, all with 1 case reported.
Conclusions
The characterization of the mut population can provide data for the personalization of follow-up. In our population, the age of hc is shown as a bias for the definition of risk, so more follow-up and multicenter studies are needed to validate the results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
166P - Metabolomic prediction of breast cancer treatment toxicities
Presenter: Max Piffoux
Session: Poster session 01
167P - A tumor immune microenvironment-based model for prediction of everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: Preliminary results from MIRACLE trial
Presenter: Tan Yujing
Session: Poster session 01
168P - HUWE1 inhibition has tumor suppressive effect in triple-negative breast cancer cell lines by modulating glycolytic and immune modulatory markers
Presenter: SHRUTI KAHOL
Session: Poster session 01
169P - Integration of metabolomics and transcriptomics to reveal potential biomarkers associated with treatment response of neoadjuvant therapy in HER2+ breast cancer
Presenter: Ningning Zhang
Session: Poster session 01
170P - Clinical significance and functional role of GPR56 (ADGRG1) in breast cancer
Presenter: Haizhu Chen
Session: Poster session 01
172P - T cell-derived circulating DNA and tumour inflammatory microenvironment in EGFR-mutant advanced non-small cell lung cancer: Correlation with the outcome of EGFR TKI treatment
Presenter: Nicha Zungsontiporn
Session: Poster session 01
173P - Expression of programmed death-ligand 1 and EGFR on circulating tumour cells in advanced lung cancer patients
Presenter: Jayant Khandare
Session: Poster session 01
174P - Frequency and prognostic value of circulating tumor cells in cancer of unknown primary
Presenter: Maria Pouyiourou
Session: Poster session 01
175P - Radiomic biomarker of vessel tortuosity for monitoring treatment change: Preliminary findings in prospective evaluation of ECOG-ACRIN EA5163
Presenter: Pushkar Mutha
Session: Poster session 01